Skip to main content
European Commission logo
Deutsch Deutsch
CORDIS - Forschungsergebnisse der EU
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

DNA helicases in genome maintenance: from molecular and cellular mechanisms to specific inhibitors as potential drugs

Projektbeschreibung

Einfluss von DNA-Helikasen auf menschliche Krankheiten als neuer therapeutischer Ansatz

Fast 100 Jahre nach der Entdeckung des DNA-Moleküls 1860 enthüllten Watson und Crick 1953 die dreidimensionale Struktur der DNA-Doppelhelix. Bei der Replikation spielen DNA-Helikasen eine wichtige Rolle: so entwinden diese Enzyme die beiden abzulesenden DNA-Stränge. Da DNA-Helikasen in vielen Zelltypen von Bakterien über Viren bis hin zu Eukaryoten konserviert sind, können sie wichtige Ansatzpunkte für neue Arzneimittel sein. Allerdings sind Struktur, Funktion und Wirkmechanismus noch nicht hinreichend geklärt. Das Projekt AntiHelix bildet eine neue Generation von Wissenschaftlern aus, die zur Rolle von DNA-Helikasen bei menschlichen Krankheiten forschen, um neue hochspezifische therapeutische Inhibitoren zu entwickeln.

Ziel

Helicases are ubiquitous enzymes, found in viruses, Bacteria, Archaea and eukaryotic cells. They act as motor proteins to separate or remodel DNA or RNA duplexes, using ATP as an energy source. Helicases play a key role in a variety of cellular processes, including DNA replication/repair/recombination, as well as RNA translation and transport. They are emerging as an important class of targets for antiviral, antibiotic and anti-cancer drugs. To date, several genetic and biochemical studies have revealed the molecular and physiological functions of DNA helicases. Moreover, protein three-dimension structural studies coupled with single molecule biophysical approaches have provided insights into structure-function relationships and reaction mechanisms of some key DNA helicases. With a consortium including experts with complementary competence and expertise in Physics, Chemistry, Biology and Clinical Oncology, and a strong commitment of companies involved in drug discovery or in the development of state-of-the-art biophysical instrumentation, we aim to: 1. obtain a detailed picture of the mechanism of action and the physiological role of a number of DNA helicases that are implicated in human diseases; 2. discover specific inhibitors of those enzymes, which can then be tested as novel therapeutic drugs, especially for cancers; 3. address the need for training next generation scientists with complementary approaches and diverse techniques by secondments in different laboratories of the consortium; 4. promote a culture of collaboration between academic and private sectors and provide young scientists with the necessary experience and skills to exploit the full potential of research findings; 5. provide early stage researchers with greater opportunities to access an increasingly competitive job market; 6. promote the values of Open Science and educate young scientists on the importance of a culture of openness, transparency, accessibility, integrity and reproducibility.

Koordinator

CONSIGLIO NAZIONALE DELLE RICERCHE
Netto-EU-Beitrag
€ 522 999,36
Adresse
PIAZZALE ALDO MORO 7
00185 Roma
Italien

Auf der Karte ansehen

Region
Centro (IT) Lazio Roma
Aktivitätstyp
Research Organisations
Links
Gesamtkosten
€ 522 999,36

Beteiligte (8)